Impact of alcohol consumption on metabolic dysfunction‐associated fatty liver disease development and remission: A longitudinal cohort study

Masahiro Sogabe,Toshiya Okahisa,Miwako Kagawa,Takanori Kashihara,Shota Fujmoto,Tomoyuki Kawaguchi,Reiko Yokoyama,Kaizo Kagemoto,Hironori Tanaka,Yoshifumi Kida,Tetsu Tomonari,Yutaka Kawano,Yasushi Sato,Masahiko Nakasono,Tetsuji Takayama
DOI: https://doi.org/10.1111/eci.14221
2024-04-20
European Journal of Clinical Investigation
Abstract:We investigated the association between changes in alcohol intake and MAFLD development and remission using a longitudinal design. We found that although the influence of alcohol intake on MAFLD development and remission differed, alcohol intake of ≥280 g/week was an advancing factor for MAFLD development in both sexes and alcohol consumption had no beneficial effects on MAFLD remission. Reducing or stopping alcohol intake is recommended for patients in MAFLD remission, as alcohol intake can eventually lead to liver fibrosis. Background The influence of alcohol intake on metabolic dysfunction‐associated fatty liver disease (MAFLD) development and remission remains unclear; thus, we aimed to investigate their longitudinal associations. Methods This observational cohort study included 6349 patients who underwent more than two health check‐ups over >2 years between April 2013 and March 2021. Generalized estimation equations were used to analyse the longitudinal associations between changes in alcohol intake and MAFLD according to repeated measures at baseline and the most recent stage. Results The MAFLD development and remission rates were 20.4 and 5.1 and 9.1 and 4.7% in men and women, respectively. Although alcohol consumption was not a significant factor for MAFLD development, consuming 0.1–69.9 g/week (odds ratio [OR]: 0.672, 95% confidence interval [CI]: 0.469–0.964, p
medicine, general & internal, research & experimental
What problem does this paper attempt to address?